These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Pediatric hospitalization for pneumococcal diseases preventable by 7-valent pneumococcal conjugate vaccine in Hong Kong. Ho PL; Chiu SS; Chow FK; Mak GC; Lau YL Vaccine; 2007 Sep; 25(39-40):6837-41. PubMed ID: 17714837 [TBL] [Abstract][Full Text] [Related]
5. [Pneumococcal infections. Every second fatality within 48 hours]. MMW Fortschr Med; 2001 Nov; 143(47):60. PubMed ID: 11791369 [No Abstract] [Full Text] [Related]
6. [A vaccination would prevent invasive pneumococcal infections in adults]. Herva E; Sankilampi U; Leinonen M Duodecim; 1997; 113(8):689-91. PubMed ID: 11466867 [No Abstract] [Full Text] [Related]
7. An economic analysis of a pneumococcal vaccine programme in people aged over 64 years in a developed country setting. Mangtani P; Roberts JA; Hall AJ; Cutts FT Int J Epidemiol; 2005 Jun; 34(3):565-74. PubMed ID: 15764694 [TBL] [Abstract][Full Text] [Related]
9. Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Fisman DN; Abrutyn E; Spaude KA; Kim A; Kirchner C; Daley J Clin Infect Dis; 2006 Apr; 42(8):1093-101. PubMed ID: 16575726 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: another view of the evidence. Fedson DS Lancet Infect Dis; 2003 May; 3(5):272-3; discussion 273-4. PubMed ID: 12726973 [No Abstract] [Full Text] [Related]
11. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Silfverdal SA; Berg S; Hemlin C; Jokinen I Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905 [TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. Chi RC; Jackson LA; Neuzil KM J Am Geriatr Soc; 2006 Jan; 54(1):115-20. PubMed ID: 16420207 [TBL] [Abstract][Full Text] [Related]
13. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Metlay JP; Fishman NO; Joffe M; Edelstein PH Vaccine; 2006 Jan; 24(4):468-75. PubMed ID: 16125826 [TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vila-Corcoles A; Salsench E; Rodriguez-Blanco T; Ochoa-Gondar O; de Diego C; Valdivieso A; Hospital I; Gomez-Bertomeu F; Raga X Vaccine; 2009 Mar; 27(10):1504-10. PubMed ID: 19171174 [TBL] [Abstract][Full Text] [Related]
17. Expected benefits of pneumococcal vaccination in Canadian infants and children < 5 years old. Can Commun Dis Rep; 2006 Mar; 32(5):45-54. PubMed ID: 16649291 [No Abstract] [Full Text] [Related]
19. Enhanced decision support for policy makers using a web interface to health-economic models--illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Hubben GA; Bos JM; Glynn DM; van der Ende A; van Alphen L; Postma MJ Vaccine; 2007 May; 25(18):3669-78. PubMed ID: 17360082 [TBL] [Abstract][Full Text] [Related]